Constipation

RedHill Biopharma Ltd (NASDAQ: RDHL) has announced new Movantik (naloxegol) Phase 3 study data analyses. The three analyses included pooled data from two Phase 3 studies involving 891 treated patients across two doses (12.5 mg and 25 mg), compared to a total of 446 patients in the...